Status:
COMPLETED
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
Lead Sponsor:
Biogen
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-65 years
Brief Summary
A phase IV, observational, survey-based study to measure compliance with Avonex® PS therapy in patients with Relapsing-Remitting Multiple Sclerosis, and to compare persistence on therapy 22 months aft...
Detailed Description
Study Design Five hundred patients will be enrolled in the prospective portion of the study, all of whom will receive AVONEX. Patients will join the study by signing the attached Informed Consent For...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS)
- Prescription of AVONEX® PS (prefilled syringes)
- Enrolment in the MS AllianceTM program
Exclusion
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00675883
Start Date
May 1 2008
End Date
December 1 2011
Last Update
January 30 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital, London Health Sciences Centre
London, Ontario, Canada